Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer

European Urology

Volumn 48, Issue 6, 2005, Pages 900-905

  Abrahamsson, P A ^a   Anderson, J ^b   Boccon Gibod, L ^c   Schulman, C ^d   Studer, U E ^e   Wirth, M ^f  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c BICHAT HOSPITAL   (France)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Androgen ablation; Anti androgen mono therapy; Deferred therapy; Immediate therapy; Prostate cancer; Side effects; Survival

Indexed keywords

ABARELIX; ANTIANDROGEN; ANTIARRHYTHMIC AGENT; BICALUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LIPID;

ADVANCED CANCER; ANEMIA; BONE DENSITY; BONE METASTASIS; BREAST TENDERNESS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE COURSE; DISEASE EXACERBATION; DRUG USE; ERECTILE DYSFUNCTION; FRACTURE; GLUCOSE INTOLERANCE; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INCIDENCE; LIBIDO DISORDER; LYMPH NODE METASTASIS; MENTAL DISEASE; MONOTHERAPY; OBSERVATION; ORCHIECTOMY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PSYCHOTRAUMA; QT PROLONGATION; RECURRENT CANCER; REFRACTORY PERIOD; URETER OBSTRUCTION;

EID: 27844514817     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.09.005     Document Type: Review

References (21)

1. A.L. Potosky, K. Knopf, L.X. Clegg, P.C. Albertsen, J.L. Stanford, and A.S. Hamilton Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study J Clin Oncol 19 2001 3750 3757
2. U.E. Studer, D. Hauri, S. Hanselmann, D. Chollet, H.J. Leisinger, and T. Gasser Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88 J Clin Oncol 22 2004 4109 4118
3. M.G. Oefelein, V. Ricchuiti, W. Conrad, A. Seftel, D. Bodner, and H. Goldman Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer J Urol 166 5 2001 1724 1728
4. H.J. Green, K.I. Pakenham, B.C. Headley, J. Yaxley, D.L. Nicol, and P.N. Mactaggart Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial BJU Int 90 4 2002 427 432
5. M. Garnick, C. Pratt, M. Campion, J. Shipley, and J.D. Bernardy Increase in the electrocardiographic QTC interval in men with prostate cancer undergoing androgen deprivation therapy: Results of three randomized controlled clinical studies Eur Urol 3 2 2004 57 (abstract no. 217)
6. D.P. Byar Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate Cancer 32 5 1973 1126 1130
7. The Medical Research Council Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial Br J Urol 79 2 1997 235 246
8. D. Kirk Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Br J Urol 86 suppl 3 2000 S220
9. U.E. Studer, P. Whelan, W. Albrecht, J. Casselmen, T. de Reijke, and D. Hauri Patients with asymptomatic prostate cancer T0-4, N0-2, M0 not suitable for local definitive treatment: do they need immediate androgen deprivation? Eur Urol 4 3 2005 p78 (abstract 303)
10. J.W. Moul, H. Wu, L. Sun, D.G. McLeod, C. Amling, and T. Donahue Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 3 2004 1141 1147
11. M.P. Wirth, W.A. See, D.G. McLeod, P. Iversen, T. Morris, K. Carroll Casodex Early Prostate Cancer Trialists' Group Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years J Urol 172 2004 1865 1870
12. P. Iversen, J.E. Johansson, P. Lodding, O. Lukkarinen, P. Lundmo, P. Klarskov Scandinavian Prostatic Cancer Group Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6 J Urol 172 2004 1871 1876
13. C.J. Tyrrell, A.V. Kaisary, P. Iversen, J.B. Anderson, L. Baert, and T. Tammela A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer Eur Urol 33 1998 447 456
14. T.H. van der Kwast, J. Schalken, J.A. Ruizeveld de Winter, C.C. van Vroonhoven, E. Mulder, and W. Boersma Androgen receptors in endocrine-therapy- resistant human prostate cancer Int J Cancer 48 2 1991 189 193
15. D. Masiello, S. Cheng, G.J. Bubley, M.L. Lu, and S.P. Balk Biaclutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor J Biol Chem 277 2002 26321 26326
16. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, and R. Vessella Molecular determinants of resistance to antiandrogens therapy Nat Med 10 2004 33 39
17. Z. Culig, J. Hoffmann, M. Erdel, I.E. Eder, A. Hobisch, and A. Hittmair Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system Br J Cancer. 81 2 1999 242 251
18. A. Hobisch, J. Hoffmann, L. Lambrinidis, I.E. Eder, G. Bartsch, and H. Klocker Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model Urol Int 65 2 2000 73 79
19. Z. Culig, G. Bartsch, and A. Hobisch Antiandrogens in prostate cancer endocrine therapy Curr Cancer Drug Targets. 4 5 2004 455 461
20. C.E. Bohl, W. Gao, D.D. Miller, C.E. Bell, and J.T. Dalton Structural basis for antagonism and resistance of bicalutamide in prostate cancer PNAS 102 2005 6201 6206
21. A. De La Taille, F. Vacherot, and L. Salomon Hormone-refractory prostate cancer: a multi-step and multi-event process Prostate Cancer Prostatic Dis 4 4 2001 204 212